Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

A highly soluble Sleeping Beauty transposase improves control of gene insertion.

Querques I, Mades A, Zuliani C, Miskey C, Alb M, Grueso E, Machwirth M, Rausch T, Einsele H, Ivics Z, Hudecek M, Barabas O.

Nat Biotechnol. 2019 Nov 4. doi: 10.1038/s41587-019-0291-z. [Epub ahead of print]

PMID:
31685959
2.

γ-Secretase inhibition increases efficacy of BCMA-specific chimeric antigen receptor T cells in multiple myeloma.

Pont MJ, Hill T, Cole GO, Abbott JJ, Kelliher J, Salter AI, Hudecek M, Comstock ML, Rajan A, Patel BKR, Voutsinas JM, Wu Q, Liu L, Cowan AJ, Wood BL, Green DJ, Riddell SR.

Blood. 2019 Nov 7;134(19):1585-1597. doi: 10.1182/blood.2019000050.

PMID:
31558469
3.

Development of adaptive immune effector therapies in solid tumors.

Comoli P, Chabannon C, Koehl U, Lanza F, Urbano-Ispizua A, Hudecek M, Ruggeri A, Secondino S, Bonini C, Pedrazzoli P.

Ann Oncol. 2019 Aug 21. pii: mdz285. doi: 10.1093/annonc/mdz285. [Epub ahead of print]

PMID:
31435646
4.

ROR1-CAR T cells are effective against lung and breast cancer in advanced microphysiologic 3D tumor models.

Wallstabe L, Göttlich C, Nelke LC, Kühnemundt J, Schwarz T, Nerreter T, Einsele H, Walles H, Dandekar G, Nietzer SL, Hudecek M.

JCI Insight. 2019 Sep 19;4(18). pii: 126345. doi: 10.1172/jci.insight.126345.

5.

Super-resolution microscopy reveals ultra-low CD19 expression on myeloma cells that triggers elimination by CD19 CAR-T.

Nerreter T, Letschert S, Götz R, Doose S, Danhof S, Einsele H, Sauer M, Hudecek M.

Nat Commun. 2019 Jul 17;10(1):3137. doi: 10.1038/s41467-019-10948-w.

6.

The tyrosine kinase inhibitor dasatinib acts as a pharmacologic on/off switch for CAR T cells.

Mestermann K, Giavridis T, Weber J, Rydzek J, Frenz S, Nerreter T, Mades A, Sadelain M, Einsele H, Hudecek M.

Sci Transl Med. 2019 Jul 3;11(499). pii: eaau5907. doi: 10.1126/scitranslmed.aau5907.

PMID:
31270272
7.

Clinical utilization of Chimeric Antigen Receptor T-cells (CAR-T) in B-cell acute lymphoblastic leukemia (ALL)-an expert opinion from the European Society for Blood and Marrow Transplantation (EBMT) and the American Society for Blood and Marrow Transplantation (ASBMT).

Kansagra AJ, Frey NV, Bar M, Laetsch TW, Carpenter PA, Savani BN, Heslop HE, Bollard CM, Komanduri KV, Gastineau DA, Chabannon C, Perales MA, Hudecek M, Aljurf M, Andritsos L, Barrett JA, Bachanova V, Bonini C, Ghobadi A, Gill SI, Hill JA, Kenderian S, Kebriaei P, Nagler A, Maloney D, Liu HD, Shah NN, Kharfan-Dabaja MA, Shpall EJ, Mufti GJ, Johnston L, Jacoby E, Bazarbachi A, DiPersio JF, Pavletic SZ, Porter DL, Grupp SA, Sadelain M, Litzow MR, Mohty M, Hashmi SK.

Bone Marrow Transplant. 2019 Nov;54(11):1868-1880. doi: 10.1038/s41409-019-0451-2. Epub 2019 May 15.

PMID:
31092900
8.

Clinical Utilization of Chimeric Antigen Receptor T Cells in B Cell Acute Lymphoblastic Leukemia: An Expert Opinion from the European Society for Blood and Marrow Transplantation and the American Society for Blood and Marrow Transplantation.

Kansagra AJ, Frey NV, Bar M, Laetsch TW, Carpenter PA, Savani BN, Heslop HE, Bollard CM, Komanduri KV, Gastineau DA, Chabannon C, Perales MA, Hudecek M, Aljurf M, Andritsos L, Barrett JA, Bachanova V, Bonini C, Ghobadi A, Gill SI, Hill J, Kenderian S, Kebriaei P, Nagler A, Maloney D, Liu HD, Shah NN, Kharfan-Dabaja MA, Shpall EJ, Mufti GJ, Johnston L, Jacoby E, Bazarbachi A, DiPersio JF, Pavletic SZ, Porter DL, Grupp SA, Sadelain M, Litzow MR, Mohty M, Hashmi SK.

Biol Blood Marrow Transplant. 2019 Mar;25(3):e76-e85. doi: 10.1016/j.bbmt.2018.12.068. Epub 2018 Dec 18.

PMID:
30576834
9.

Chimeric Antigen Receptor Library Screening Using a Novel NF-κB/NFAT Reporter Cell Platform.

Rydzek J, Nerreter T, Peng H, Jutz S, Leitner J, Steinberger P, Einsele H, Rader C, Hudecek M.

Mol Ther. 2019 Feb 6;27(2):287-299. doi: 10.1016/j.ymthe.2018.11.015. Epub 2018 Nov 20.

PMID:
30573301
10.

CAR T cells targeting αvβ3 integrin are effective against advanced cancer in preclinical models.

Wallstabe L, Mades A, Frenz S, Einsele H, Rader C, Hudecek M.

Adv Cell Gene Ther. 2018 Sep;1(2). pii: e11. doi: 10.1002/acg2.11. Epub 2018 Jul 10.

11.

Non-viral therapeutic cell engineering with the Sleeping Beauty transposon system.

Hudecek M, Ivics Z.

Curr Opin Genet Dev. 2018 Oct;52:100-108. doi: 10.1016/j.gde.2018.06.003. Epub 2018 Oct 12. Review.

PMID:
29957586
12.

CARs and other T cell therapies for MM: The clinical experience.

Danhof S, Hudecek M, Smith EL.

Best Pract Res Clin Haematol. 2018 Jun;31(2):147-157. doi: 10.1016/j.beha.2018.03.002. Epub 2018 Mar 27. Review.

13.

Novel targets and technologies for CAR-T cells in multiple myeloma and acute myeloid leukemia.

Prommersberger S, Jetani H, Danhof S, Monjezi R, Nerreter T, Beckmann J, Einsele H, Hudecek M.

Curr Res Transl Med. 2018 May;66(2):37-38. doi: 10.1016/j.retram.2018.03.006. Epub 2018 Apr 11. No abstract available.

PMID:
29655962
14.

CAR T-cells targeting FLT3 have potent activity against FLT3-ITD+ AML and act synergistically with the FLT3-inhibitor crenolanib.

Jetani H, Garcia-Cadenas I, Nerreter T, Thomas S, Rydzek J, Meijide JB, Bonig H, Herr W, Sierra J, Einsele H, Hudecek M.

Leukemia. 2018 May;32(5):1168-1179. doi: 10.1038/s41375-018-0009-0. Epub 2018 Feb 5.

PMID:
29472720
15.

Current developments in immunotherapy in the treatment of multiple myeloma.

Köhler M, Greil C, Hudecek M, Lonial S, Raje N, Wäsch R, Engelhardt M.

Cancer. 2018 May 15;124(10):2075-2085. doi: 10.1002/cncr.31243. Epub 2018 Feb 6. Review.

16.

Expression of programmed death-1 on lymphocytes in myeloma patients is lowered during lenalidomide maintenance.

Danhof S, Schreder M, Knop S, Rasche L, Strifler S, Löffler C, Gogishvili T, Einsele H, Hudecek M.

Haematologica. 2018 Mar;103(3):e126-e129. doi: 10.3324/haematol.2017.178947. Epub 2017 Nov 30. No abstract available.

17.

SLAMF7-CAR T cells eliminate myeloma and confer selective fratricide of SLAMF7+ normal lymphocytes.

Gogishvili T, Danhof S, Prommersberger S, Rydzek J, Schreder M, Brede C, Einsele H, Hudecek M.

Blood. 2017 Dec 28;130(26):2838-2847. doi: 10.1182/blood-2017-04-778423. Epub 2017 Oct 31.

PMID:
29089311
18.

Mining Naïve Rabbit Antibody Repertoires by Phage Display for Monoclonal Antibodies of Therapeutic Utility.

Peng H, Nerreter T, Chang J, Qi J, Li X, Karunadharma P, Martinez GJ, Fallahi M, Soden J, Freeth J, Beerli RR, Grawunder U, Hudecek M, Rader C.

J Mol Biol. 2017 Sep 15;429(19):2954-2973. doi: 10.1016/j.jmb.2017.08.003. Epub 2017 Aug 14.

19.

Panobinostat induces CD38 upregulation and augments the antimyeloma efficacy of daratumumab.

García-Guerrero E, Gogishvili T, Danhof S, Schreder M, Pallaud C, Pérez-Simón JA, Einsele H, Hudecek M.

Blood. 2017 Jun 22;129(25):3386-3388. doi: 10.1182/blood-2017-03-770776. Epub 2017 May 5. No abstract available.

PMID:
28476749
20.

Going non-viral: the Sleeping Beauty transposon system breaks on through to the clinical side.

Hudecek M, Izsvák Z, Johnen S, Renner M, Thumann G, Ivics Z.

Crit Rev Biochem Mol Biol. 2017 Aug;52(4):355-380. doi: 10.1080/10409238.2017.1304354. Epub 2017 Apr 12. Review. Erratum in: Crit Rev Biochem Mol Biol. 2017 Aug;52(4):i.

PMID:
28402189
21.

Minicircle-Based Engineering of Chimeric Antigen Receptor (CAR) T Cells.

Hudecek M, Gogishvili T, Monjezi R, Wegner J, Shankar R, Kruesemann C, Miskey C, Ivics Z, Schmeer M, Schleef M.

Recent Results Cancer Res. 2016;209:37-50. doi: 10.1007/978-3-319-42934-2_3. Review.

PMID:
28101686
22.

Targeted antibody-mediated depletion of murine CD19 CAR T cells permanently reverses B cell aplasia.

Paszkiewicz PJ, Fräßle SP, Srivastava S, Sommermeyer D, Hudecek M, Drexler I, Sadelain M, Liu L, Jensen MC, Riddell SR, Busch DH.

J Clin Invest. 2016 Nov 1;126(11):4262-4272. doi: 10.1172/JCI84813. Epub 2016 Oct 17.

23.

Myeloma CARs are rolling into the clinical arena.

Hudecek M, Einsele H.

Blood. 2016 Sep 29;128(13):1667-8. doi: 10.1182/blood-2016-08-729467. No abstract available.

PMID:
27688779
24.

Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8+ and CD4+ CD19-specific chimeric antigen receptor-modified T cells.

Turtle CJ, Hanafi LA, Berger C, Hudecek M, Pender B, Robinson E, Hawkins R, Chaney C, Cherian S, Chen X, Soma L, Wood B, Li D, Heimfeld S, Riddell SR, Maloney DG.

Sci Transl Med. 2016 Sep 7;8(355):355ra116. doi: 10.1126/scitranslmed.aaf8621.

25.

Enhanced CAR T-cell engineering using non-viral Sleeping Beauty transposition from minicircle vectors.

Monjezi R, Miskey C, Gogishvili T, Schleef M, Schmeer M, Einsele H, Ivics Z, Hudecek M.

Leukemia. 2017 Jan;31(1):186-194. doi: 10.1038/leu.2016.180. Epub 2016 Jun 24.

PMID:
27491640
26.

CD19 CAR-T cells of defined CD4+:CD8+ composition in adult B cell ALL patients.

Turtle CJ, Hanafi LA, Berger C, Gooley TA, Cherian S, Hudecek M, Sommermeyer D, Melville K, Pender B, Budiarto TM, Robinson E, Steevens NN, Chaney C, Soma L, Chen X, Yeung C, Wood B, Li D, Cao J, Heimfeld S, Jensen MC, Riddell SR, Maloney DG.

J Clin Invest. 2016 Jun 1;126(6):2123-38. doi: 10.1172/JCI85309. Epub 2016 Apr 25.

27.

Chimeric antigen receptor-modified T cells derived from defined CD8+ and CD4+ subsets confer superior antitumor reactivity in vivo.

Sommermeyer D, Hudecek M, Kosasih PL, Gogishvili T, Maloney DG, Turtle CJ, Riddell SR.

Leukemia. 2016 Feb;30(2):492-500. doi: 10.1038/leu.2015.247. Epub 2015 Sep 15.

28.

[Children's Aggressive Behaviour and Therapeutic Interventions on the Parental Couple Level].

Lux U, Hudecek M.

Prax Kinderpsychol Kinderpsychiatr. 2015;64(1):48-60. doi: 10.13109/prkk.2015.64.1.48. German.

PMID:
25609393
29.

Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells.

Berger C, Sommermeyer D, Hudecek M, Berger M, Balakrishnan A, Paszkiewicz PJ, Kosasih PL, Rader C, Riddell SR.

Cancer Immunol Res. 2015 Feb;3(2):206-16. doi: 10.1158/2326-6066.CIR-14-0163. Epub 2014 Oct 29.

30.

The nonsignaling extracellular spacer domain of chimeric antigen receptors is decisive for in vivo antitumor activity.

Hudecek M, Sommermeyer D, Kosasih PL, Silva-Benedict A, Liu L, Rader C, Jensen MC, Riddell SR.

Cancer Immunol Res. 2015 Feb;3(2):125-35. doi: 10.1158/2326-6066.CIR-14-0127. Epub 2014 Sep 11.

31.

Adoptive therapy with chimeric antigen receptor-modified T cells of defined subset composition.

Riddell SR, Sommermeyer D, Berger C, Liu LS, Balakrishnan A, Salter A, Hudecek M, Maloney DG, Turtle CJ.

Cancer J. 2014 Mar-Apr;20(2):141-4. doi: 10.1097/PPO.0000000000000036. Review.

32.

Receptor affinity and extracellular domain modifications affect tumor recognition by ROR1-specific chimeric antigen receptor T cells.

Hudecek M, Lupo-Stanghellini MT, Kosasih PL, Sommermeyer D, Jensen MC, Rader C, Riddell SR.

Clin Cancer Res. 2013 Jun 15;19(12):3153-64. doi: 10.1158/1078-0432.CCR-13-0330. Epub 2013 Apr 25.

33.

Engineered T cells for anti-cancer therapy.

Turtle CJ, Hudecek M, Jensen MC, Riddell SR.

Curr Opin Immunol. 2012 Oct;24(5):633-9. doi: 10.1016/j.coi.2012.06.004. Epub 2012 Jul 18. Review.

34.

Cyclin-A1 represents a new immunogenic targetable antigen expressed in acute myeloid leukemia stem cells with characteristics of a cancer-testis antigen.

Ochsenreither S, Majeti R, Schmitt T, Stirewalt D, Keilholz U, Loeb KR, Wood B, Choi YE, Bleakley M, Warren EH, Hudecek M, Akatsuka Y, Weissman IL, Greenberg PD.

Blood. 2012 Jun 7;119(23):5492-501. doi: 10.1182/blood-2011-07-365890. Epub 2012 Apr 23.

35.

Adoptive T-cell therapy for B-cell malignancies.

Hudecek M, Anderson LD Jr, Nishida T, Riddell SR.

Expert Rev Hematol. 2009 Oct;2(5):517-32. doi: 10.1586/ehm.09.47. Review.

36.

The B-cell tumor-associated antigen ROR1 can be targeted with T cells modified to express a ROR1-specific chimeric antigen receptor.

Hudecek M, Schmitt TM, Baskar S, Lupo-Stanghellini MT, Nishida T, Yamamoto TN, Bleakley M, Turtle CJ, Chang WC, Greisman HA, Wood B, Maloney DG, Jensen MC, Rader C, Riddell SR.

Blood. 2010 Nov 25;116(22):4532-41. doi: 10.1182/blood-2010-05-283309. Epub 2010 Aug 11.

37.

Leukemia-associated minor histocompatibility antigen discovery using T-cell clones isolated by in vitro stimulation of naive CD8+ T cells.

Bleakley M, Otterud BE, Richardt JL, Mollerup AD, Hudecek M, Nishida T, Chaney CN, Warren EH, Leppert MF, Riddell SR.

Blood. 2010 Jun 10;115(23):4923-33. doi: 10.1182/blood-2009-12-260539. Epub 2010 Mar 4.

38.

Recognition and killing of brain tumor stem-like initiating cells by CD8+ cytolytic T cells.

Brown CE, Starr R, Martinez C, Aguilar B, D'Apuzzo M, Todorov I, Shih CC, Badie B, Hudecek M, Riddell SR, Jensen MC.

Cancer Res. 2009 Dec 1;69(23):8886-93. doi: 10.1158/0008-5472.CAN-09-2687. Epub 2009 Nov 10.

39.

Development of tumor-reactive T cells after nonmyeloablative allogeneic hematopoietic stem cell transplant for chronic lymphocytic leukemia.

Nishida T, Hudecek M, Kostic A, Bleakley M, Warren EH, Maloney D, Storb R, Riddell SR.

Clin Cancer Res. 2009 Jul 15;15(14):4759-68. doi: 10.1158/1078-0432.CCR-09-0199. Epub 2009 Jun 30.

40.

Mesenchymal stem cells remain host-derived independent of the source of the stem-cell graft and conditioning regimen used.

Bartsch K, Al-Ali H, Reinhardt A, Franke C, Hudecek M, Kamprad M, Tschiedel S, Cross M, Niederwieser D, Gentilini C.

Transplantation. 2009 Jan 27;87(2):217-21. doi: 10.1097/TP.0b013e3181938998.

PMID:
19155975
41.

[Minor antigens - major impact. The role of minor histocompatibility antigens in allogeneic hematopoietic stem cell transplantation].

Hudecek M, Bartsch K, Tschiedel S, Niederwieser D.

Dtsch Med Wochenschr. 2008 Jul;133(28-29):1511-6. doi: 10.1055/s-2008-1081100. Review. German.

PMID:
18597211
42.

Spontaneous remission of acute myeloid leukemia relapse after hematopoietic cell transplantation in a high-risk patient with 11q23/MLL abnormality.

Hudecek M, Bartsch K, Jäkel N, Heyn S, Pfannes R, Al-Ali HK, Cross M, Pönisch W, Gerecke U, Edelmann J, Ittel T, Niederwieser D.

Acta Haematol. 2008;119(2):111-4. doi: 10.1159/000121827. Epub 2008 Mar 27.

PMID:
18367831
43.

[Utilization of the interrelationship of mucoproteins and SGOT in the diagnosis of hepatobiliary tract diseases].

Velkov J, Topercer M, Hudecek M.

Bratisl Lek Listy. 1966 Oct 31;46(8):478-86. Czech. No abstract available.

PMID:
5977423
44.

[Disinfection of patients' rooms using peracetic acid].

Vykydal A, Hudecek M, Kincl J.

Cesk Epidemiol Mikrobiol Imunol. 1966 Jul;15(4):234-41. Czech. No abstract available.

PMID:
4224557

Supplemental Content

Loading ...
Support Center